- Home
- MUJ vs AUTL Comparison
MUJ vs AUTL Comparison
Compare MUJ & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- AUTL
- Stock Information
- Founded
- MUJ 1998
- AUTL 2014
- Country
- MUJ United States
- AUTL United Kingdom
- Employees
- MUJ N/A
- AUTL N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUJ Finance
- AUTL Health Care
- Exchange
- MUJ Nasdaq
- AUTL Nasdaq
- Market Cap
- MUJ 602.6M
- AUTL 590.8M
- IPO Year
- MUJ N/A
- AUTL 2018
- Fundamental
- Price
- MUJ $11.58
- AUTL $2.17
- Analyst Decision
- MUJ
- AUTL Strong Buy
- Analyst Count
- MUJ 0
- AUTL 3
- Target Price
- MUJ N/A
- AUTL $10.20
- AVG Volume (30 Days)
- MUJ 108.0K
- AUTL 1.1M
- Earning Date
- MUJ 01-01-0001
- AUTL 03-13-2025
- Dividend Yield
- MUJ 4.36%
- AUTL N/A
- EPS Growth
- MUJ N/A
- AUTL N/A
- EPS
- MUJ N/A
- AUTL N/A
- Revenue
- MUJ N/A
- AUTL $10,091,000.00
- Revenue This Year
- MUJ N/A
- AUTL $851.83
- Revenue Next Year
- MUJ N/A
- AUTL $224.65
- P/E Ratio
- MUJ N/A
- AUTL N/A
- Revenue Growth
- MUJ N/A
- AUTL 82.71
- 52 Week Low
- MUJ $9.74
- AUTL $2.07
- 52 Week High
- MUJ $11.70
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- MUJ 60.77
- AUTL 41.40
- Support Level
- MUJ $11.31
- AUTL $2.07
- Resistance Level
- MUJ $11.39
- AUTL $2.26
- Average True Range (ATR)
- MUJ 0.09
- AUTL 0.12
- MACD
- MUJ 0.03
- AUTL 0.01
- Stochastic Oscillator
- MUJ 100.00
- AUTL 25.00
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.